Rudd RM - Search Results

1

Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma.

Fennell DA, Steele JP, Shamash J, Evans MT, Wells P, Sheaff MT, Rudd RM, Stebbing J. Fennell DA, et al. Among authors: rudd rm. Cancer. 2007 Jan 1;109(1):93-9. doi: 10.1002/cncr.22366. Cancer. 2007. PMID: 17146783 Free article.

2

Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials.

Fennell DA, Parmar A, Shamash J, Evans MT, Sheaff MT, Sylvester R, Dhaliwal K, Gower N, Steele J, Rudd R. Fennell DA, et al. J Clin Oncol. 2005 Jan 1;23(1):184-9. doi: 10.1200/JCO.2005.07.050. J Clin Oncol. 2005. PMID: 15625372

3

Phase II trial of irinotecan, cisplatin and mitomycin for relapsed small cell lung cancer.

Fennell DA, Steele JP, Shamash J, Slater SE, Sheaff MT, Wells P, Rudd RM, Stebbing J. Fennell DA, et al. Among authors: rudd rm. Int J Cancer. 2007 Dec 1;121(11):2575-7. doi: 10.1002/ijc.22984. Int J Cancer. 2007. PMID: 17680556 Clinical Trial.

4

The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.

Stebbing J, Powles T, McPherson K, Shamash J, Wells P, Sheaff MT, Slater S, Rudd RM, Fennell D, Steele JP. Stebbing J, et al. Among authors: rudd rm. Lung Cancer. 2009 Jan;63(1):94-7. doi: 10.1016/j.lungcan.2008.04.001. Epub 2008 May 16. Lung Cancer. 2009. PMID: 18486273

5

Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development.

Fennell DA, Rudd RM. Fennell DA, et al. Among authors: rudd rm. Lancet Oncol. 2004 Jun;5(6):354-62. doi: 10.1016/S1470-2045(04)01492-5. Lancet Oncol. 2004. PMID: 15172356 Review.

6

Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma.

Fennell DA, C Steele JP, Shamash J, Sheaff MT, Evans MT, Goonewardene TI, Nystrom ML, Gower NH, Rudd RM. Fennell DA, et al. Among authors: rudd rm. Lung Cancer. 2005 Feb;47(2):277-81. doi: 10.1016/j.lungcan.2004.08.005. Lung Cancer. 2005. PMID: 15639727 Clinical Trial.

7

Prognostic factors in mesothelioma.

Steele JP, Klabatsa A, Fennell DA, Palläska A, Sheaff MT, Evans MT, Shamash J, Rudd RM. Steele JP, et al. Among authors: rudd rm. Lung Cancer. 2005 Jul;49 Suppl 1:S49-52. doi: 10.1016/j.lungcan.2005.03.009. Lung Cancer. 2005. PMID: 15894403

8

In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion.

Szlosarek PW, Klabatsa A, Pallaska A, Sheaff M, Smith P, Crook T, Grimshaw MJ, Steele JP, Rudd RM, Balkwill FR, Fennell DA. Szlosarek PW, et al. Among authors: rudd rm. Clin Cancer Res. 2006 Dec 1;12(23):7126-31. doi: 10.1158/1078-0432.CCR-06-1101. Clin Cancer Res. 2006. PMID: 17145837

9

Phase II study of vinorelbine in patients with malignant pleural mesothelioma.

Steele JP, Shamash J, Evans MT, Gower NH, Tischkowitz MD, Rudd RM. Steele JP, et al. Among authors: rudd rm. J Clin Oncol. 2000 Dec 1;18(23):3912-7. doi: 10.1200/JCO.2000.18.23.3912. J Clin Oncol. 2000. PMID: 11099320 Clinical Trial.

10

Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma.

Steele JP, O'Doherty CA, Shamash J, Evans MT, Gower NH, Tischkowitz MD, Rudd RM. Steele JP, et al. Among authors: rudd rm. Ann Oncol. 2001 Apr;12(4):497-9. doi: 10.1023/a:1011139918558. Ann Oncol. 2001. PMID: 11398882 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

135 results

Search Page

Filters